The EPS beat and $1B buyback provide near-term support, but the 35% revenue decline and widening losses underscore the COVID-19 revenue cliff. Watch for pumitamig Phase 2 data at ASCO (May 29-June 2) and gotistobart interim Phase 3 data in 2026 — positive readouts could re-rate the stock on oncology optionality. The manufacturing restructuring signals management is serious about cost discipline, but execution risk is high.
Price Chart
Executive Summary
BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY) and a GAAP net loss of €531.9M (diluted EPS -€2.10), which beat the consensus EPS estimate of -$1.92 by ~35%. The company reaffirmed full-year 2026 revenue guidance of €2.0B-€2.3B and announced a planned $1B share repurchase program and a major manufacturing footprint consolidation expected to yield ~€500M in annual savings by 2029. However, the core COVID-19 vaccine business continues to decline, and the oncology pipeline, while advancing with multiple pivotal trial initiations, remains pre-commercial.
Key Financial Metrics
Key Facts
- Q1 2026 revenue €118.1M vs €182.8M YoY (-35%), driven by lower COVID-19 vaccine sales
- GAAP diluted EPS -€2.10 (-$2.46) vs consensus -$1.92 — a 34.9% beat
- Net loss widened to -€531.9M from -€415.8M YoY; adjusted net loss -€494.6M
- Reaffirmed FY2026 revenue guidance €2.0B-€2.3B and adjusted R&D spend €2.2B-€2.5B
- Planned $1.0B ADS repurchase program over 12 months for capital efficiency
- Manufacturing footprint consolidation to exit Idar-Oberstein, Marburg, Singapore, and CureVac sites, affecting ~1,860 positions; ~€500M annual savings targeted by 2029
- Five pivotal trials for pumitamig (PD-L1/VEGF-A bispecific) initiated in Q1 2026 in collaboration with BMS
- Cash, cash equivalents, and security investments of €16.8B as of March 31, 2026
- Co-founders Sahin and Türeci to transition to new mRNA company by end of 2026; CEO search initiated
Financial Impact
Revenue decline of €64.7M YoY (-35%); net loss increased by €116.1M; $1B buyback authorized; ~€500M annual cost savings targeted by 2029
Risk Factors
- COVID-19 vaccine revenue continues to decline faster than oncology pipeline can offset
- Manufacturing consolidation may incur significant upfront exit costs and operational disruption
- Co-founder transition creates leadership uncertainty; new CEO appointment is a key overhang
- Oncology pipeline remains pre-revenue; late-stage trial failures would reset valuation
- $1B buyback may be viewed as capital allocation signal but does not fix declining fundamentals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287464 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.61 (+5.36%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.61 (−12.88%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.61 (+4.10%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.61 (−5.75%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.61 (+4.04%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.61 (+12.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access